PL1663185T3 - Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego - Google Patents

Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego

Info

Publication number
PL1663185T3
PL1663185T3 PL04765458T PL04765458T PL1663185T3 PL 1663185 T3 PL1663185 T3 PL 1663185T3 PL 04765458 T PL04765458 T PL 04765458T PL 04765458 T PL04765458 T PL 04765458T PL 1663185 T3 PL1663185 T3 PL 1663185T3
Authority
PL
Poland
Prior art keywords
inflammation
immune
induced
prevention
treatment
Prior art date
Application number
PL04765458T
Other languages
English (en)
Inventor
Thomas Wilckens
Volkmann Ariane
Original Assignee
Onepharm Res & Development Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onepharm Res & Development Gmbh filed Critical Onepharm Res & Development Gmbh
Publication of PL1663185T3 publication Critical patent/PL1663185T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Veneer Processing And Manufacture Of Plywood (AREA)
PL04765458T 2003-09-22 2004-09-21 Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego PL1663185T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50471703P 2003-09-22 2003-09-22
EP04765458A EP1663185B1 (en) 2003-09-22 2004-09-21 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
PCT/EP2004/010582 WO2005027882A1 (en) 2003-09-22 2004-09-21 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss

Publications (1)

Publication Number Publication Date
PL1663185T3 true PL1663185T3 (pl) 2009-06-30

Family

ID=34375537

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04765458T PL1663185T3 (pl) 2003-09-22 2004-09-21 Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego

Country Status (15)

Country Link
US (2) US20100087413A1 (pl)
EP (2) EP2036548A1 (pl)
JP (1) JP2007533625A (pl)
AT (1) ATE416761T1 (pl)
AU (1) AU2004273610B2 (pl)
CA (1) CA2539741A1 (pl)
CY (1) CY1111246T1 (pl)
DE (1) DE602004018338D1 (pl)
DK (1) DK1663185T3 (pl)
ES (1) ES2317029T3 (pl)
NZ (1) NZ546062A (pl)
PL (1) PL1663185T3 (pl)
PT (1) PT1663185E (pl)
SI (1) SI1663185T1 (pl)
WO (1) WO2005027882A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579089A1 (en) * 2004-08-30 2006-03-09 Government Of The United States Of America As Represented By The Secreta Ry Department Of Health And Human Services Inhibition of viruses using rnase h inhibitors
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
DE102005026231A1 (de) * 2005-06-07 2006-12-14 Origenis Ag Peptid-Deformylase (PDF) Inhibitoren 3
PL1864667T3 (pl) * 2006-06-01 2014-01-31 Santen Sas Zastosowanie proleków do podania do ciała szklistego oka
JP5283620B2 (ja) 2006-07-06 2013-09-04 グラクソ グループ リミテッド Ｐ２ｘ７受容体アンタゴニストとしての置換ｎ−フェニルメチル−５−オキソ−プロリン−２−アミドおよびそれらの使用方法
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
KR101022809B1 (ko) * 2008-02-05 2011-03-17 재단법인서울대학교산학협력재단 면역조절에 의한 캔디다알비칸스 기인성 질환의 치료
EP2336109A4 (en) * 2008-09-25 2012-05-02 Shionogi & Co NOVEL PYRROLINONE DERIVATIVE AND DRUG COMPOSITION CONTAINING THE SAME
US8822462B2 (en) * 2009-01-28 2014-09-02 Emory University Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
JP2012041291A (ja) * 2010-08-18 2012-03-01 Institute Of Physical & Chemical Research 歯周病の治療または予防剤
ITRM20100614A1 (it) * 2010-11-24 2012-05-25 D M G Italia S R L Preparazioni farmaceutiche dell acido 18 beta glicirretico e/o di suoi derivati per infiltrazioni intrarticolari per il trattamento delle artropatie infiammatorie
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9890166B2 (en) 2013-05-27 2018-02-13 Novartis Ag Imidazopyrrolidine derivatives and their use in the treatment of disease
PT3004108T (pt) 2013-05-28 2018-01-24 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
US9714249B2 (en) 2013-05-28 2017-07-25 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
US9550796B2 (en) 2013-11-21 2017-01-24 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors
CN104873520A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其用途
CN104873521A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其应用
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
UA126584C2 (uk) * 2017-08-04 2022-11-02 Арделікс, Інк. Похідні гліцирретинової кислоти для лікування гіперкаліємії
GB201805100D0 (en) * 2018-03-28 2018-05-09 Benevolentai Bio Ltd Treatment of sarcopenic diseases
AU2020218255A1 (en) 2019-02-07 2021-09-09 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262851A (en) * 1958-06-26 1966-07-26 Biorex Laboratories Ltd Pharmacological compositions containing glycyrrhetinic acid derivative
DE2050072C3 (de) * 1970-10-12 1975-01-30 Inverni Della Beffa S.P.A., Mailand (Italien) Aluminium-tri-3-acetyl-18 betaglycyrrthetinat, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zubereitungen
US3934027A (en) * 1973-05-03 1976-01-20 Pfizer Inc. 18β-Glycyrrhetinic acid amides useful as antiulcer agents
EP0496520A1 (en) * 1991-01-22 1992-07-29 Merck & Co. Inc. Novel bone acting agents
GB2261672A (en) * 1991-11-18 1993-05-26 Michael Braden The use of biomaterials for tissue repair
JPH07291857A (ja) * 1994-04-27 1995-11-07 Suntory Ltd グリチルレチン酸化合物を有効成分とする骨疾患の予防及び治療剤
DE19951970A1 (de) * 1999-10-28 2001-05-03 Bionetworks Gmbh Arzneimittel für die Toleranzinduktion
US20050048007A1 (en) * 2000-11-02 2005-03-03 Inobys Ltd. Plaque reducing composition
GB0105772D0 (en) 2001-03-08 2001-04-25 Sterix Ltd Use
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
WO2003044000A1 (en) 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PL370111A1 (pl) 2001-11-22 2005-05-16 Biovitrum Ab Inhibitory dehydrogenazy 11-beta-hydroksysteroidów typu I
EP1474139B1 (en) 2002-02-01 2007-11-21 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
WO2004027042A2 (en) 2002-09-23 2004-04-01 E. I. Du Pont De Nemours And Company Isolation and use of ryanodine receptors
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US20030148349A1 (en) * 2003-01-03 2003-08-07 Shyam Ramakrishnan Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
SI1663185T1 (sl) 2009-04-30
PT1663185E (pt) 2009-02-16
AU2004273610B2 (en) 2010-07-01
DE602004018338D1 (de) 2009-01-22
EP1663185B1 (en) 2008-12-10
ES2317029T3 (es) 2009-04-16
US20110275584A1 (en) 2011-11-10
US20100087413A1 (en) 2010-04-08
EP2036548A1 (en) 2009-03-18
WO2005027882A1 (en) 2005-03-31
CY1111246T1 (el) 2015-06-11
ATE416761T1 (de) 2008-12-15
NZ546062A (en) 2009-09-25
JP2007533625A (ja) 2007-11-22
EP1663185A1 (en) 2006-06-07
CA2539741A1 (en) 2005-03-31
AU2004273610A1 (en) 2005-03-31
DK1663185T3 (da) 2009-04-06

Similar Documents

Publication Publication Date Title
PL1663185T3 (pl) Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego
GB0223040D0 (en) Therapeutic compounds
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
HK1129103A1 (en) Prodrugs of gaba analogs, compositions and uses thereof gaba
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
IL161070A0 (en) Compositions for the treatment of infectious diseases
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
EP1461076A4 (en) METHODS AND COMPOSITIONS FOR TREATING LESIONS OF RESPIRATORY EPITHELIUM
MXPA04003755A (es) Endoprotesis vasculares.
AU2003211610A1 (en) Pharmaceutical compositions for the treatment or prevention of osteoporosis
EP1443918A4 (en) CALCIUM-L-THREONATE FOR PREVENTING OR TREATING BONE FRACTURES
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
GB2392838B (en) Calcium L-threonate for preventing or treating cartilage related diseases
AUPR809001A0 (en) Compositions for the treatment and prevention of plant pathogens
AU2001273759A1 (en) Essential oils and chemically related species for the treatment of increased bone resorption
EP1457210A4 (en) THERAPEUTIC AND / OR PROPHYLACTIC AGENTS FOR CONFORMATIONAL DISEASES
IL159511A0 (en) Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
WO2003011309A3 (de) Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie
MXPA03006468A (es) Composiciones para la prevencion o tratamiento de hepatopatia.
IL164536A0 (en) The use of hydroxypyridone-derivatives in wound healing